Kuk Hyoun Hwang - Mar 23, 2023 Form 4 Insider Report for Bellevue Life Sciences Acquisition Corp. (BLAC)

Role: Chief Executive Officer, Director, 10%+ Owner
Signature: /s/ Kuk Hyoun Hwang
Stock symbol: BLAC
Transactions as of: Mar 23, 2023
Transactions value $: $0
Form type: 4
Date filed: 3/27/2023, 04:09 PM
Previous filing: Feb 23, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BLAC	Common Stock	Other	$0	-20K	-0.99%	$0.00	2M	Mar 23, 2023	By Bellevue Global Life Sciences Investors LLC	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BLAC	Warrant for Common Stock	Other	$0	-20K	-5.13%	$0.00	370K	Mar 23, 2023	Common Stock	20K	$11.50	By Bellevue Global Life Sciences Investors LLC	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC the sponsor of the Issuer (the "Sponsor"), whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor.
F2	Represents the shares transferred by the Sponsor to Mr. David Jin Yoo for service as Chief Financial Officer.
F3	Represents the warrant to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Mr. David Jin Yoo for his service as Chief Financial Officer. Each warrant will become exercisable 30 days after the Issuer's initial business combination. Each warrant will expire five years after the completion of the Issuer's initial business combination, or earlier upon redemption or liquidation. Each warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustments.